• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病足综合征中的组织型纤溶酶原激活剂(t-PA)和1型纤溶酶原激活剂抑制剂(PAI-1)

Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.

作者信息

Kulwas Arleta, Lisewska Beata, Jundziłł Wiesław, Ruszkowska Barbara, Drewniak Wanda, Ruprecht Zofia, Gadomska Grażyna, Rość Danuta

机构信息

Department of Pathophysiology, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.

Department of Pathophysiology, Collegium Medicum of Nicolaus Copernicus University, Bydgoszcz, Poland.

出版信息

Adv Med Sci. 2017 Mar;62(1):87-91. doi: 10.1016/j.advms.2016.07.007. Epub 2017 Feb 11.

DOI:10.1016/j.advms.2016.07.007
PMID:28193577
Abstract

PURPOSE

The aim was to evaluate tissue plasminogen activator (tPA) and plasminogen activator inhibitor type 1 (PAI-1) concentration using enzyme linked immunosorbent assay method (ELISA) in diabetic foot syndrome (DFS) as compared to a group of healthy people and patients with diabetes mellitus without symptomatic vascular complications (DM2T).

MATERIAL/METHODS: Venous blood samples were collected from 90 patients with type 2 diabetes mellitus (30 - DM2T; 60 - DFS). Age-matched controls were also included (n=30). tPA and PAI-1 plasma levels were measured by enzyme-linked immunosorbent assay (ELISA).

RESULTS

We found a significantly lower concentration of tPA:Ag in patients with DFS in comparison to the DM2T group; tPA concentrations were significantly higher in DM2T as compared to the control group. We observed significantly lower concentration of PAI-1:Ag in DF patients treated for hypertension as compared to patients without hypertension. The tPA:Ag and PAI-1:Ag concentration analysis in DFS depending on age, gender and BMI did not show any significant differences.

CONCLUSIONS

A lower concentration of tPA in patients with DFS may be associated with damage to the endothelial cells, especially in the microvasculature, and the sympathetic nervous system.

摘要

目的

旨在采用酶联免疫吸附测定法(ELISA)评估糖尿病足综合征(DFS)患者组织型纤溶酶原激活剂(tPA)和纤溶酶原激活物抑制剂1型(PAI-1)的浓度,并与一组健康人和无血管并发症症状的糖尿病患者(DM2T)进行比较。

材料/方法:采集90例2型糖尿病患者(30例DM2T;60例DFS)的静脉血样本。还纳入了年龄匹配的对照组(n = 30)。采用酶联免疫吸附测定法(ELISA)检测tPA和PAI-1的血浆水平。

结果

我们发现,与DM2T组相比,DFS患者的tPA:Ag浓度显著降低;与对照组相比,DM2T组的tPA浓度显著升高。我们观察到,与未患高血压的患者相比,接受高血压治疗的DFS患者的PAI-1:Ag浓度显著降低。根据年龄、性别和体重指数对DFS患者的tPA:Ag和PAI-1:Ag浓度进行分析,未发现任何显著差异。

结论

DFS患者tPA浓度较低可能与内皮细胞损伤有关,尤其是在微血管系统和交感神经系统中。

相似文献

1
Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) in diabetic foot syndrome.糖尿病足综合征中的组织型纤溶酶原激活剂(t-PA)和1型纤溶酶原激活剂抑制剂(PAI-1)
Adv Med Sci. 2017 Mar;62(1):87-91. doi: 10.1016/j.advms.2016.07.007. Epub 2017 Feb 11.
2
Peripheral artery disease in type 2 diabetes: the role of fibrinolysis.2型糖尿病中的外周动脉疾病:纤维蛋白溶解的作用
Thromb Haemost. 2003 Jan;89(1):91-6.
3
Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.马来西亚人群中纤溶酶原激活物抑制剂-1 和组织型纤溶酶原激活物与 2 型糖尿病及代谢综合征的相关性。
Cardiovasc Diabetol. 2011 Mar 18;10:23. doi: 10.1186/1475-2840-10-23.
4
Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.科威特高脂血症患者的脂蛋白(a)、组织纤溶酶原激活物和纤溶酶原激活物抑制剂1水平
Eur J Clin Invest. 1997 May;27(5):380-6. doi: 10.1046/j.1365-2362.1997.1230671.x.
5
Association between Plasma Levels of PAI-1, tPA/PAI-1 Molar Ratio, and Mild Cognitive Impairment in Chinese Patients with Type 2 Diabetes Mellitus.血浆 PAI-1 水平、tPA/PAI-1 摩尔比与中国 2 型糖尿病患者轻度认知功能障碍的关系。
J Alzheimers Dis. 2018;63(2):835-845. doi: 10.3233/JAD-171038.
6
Tissue plasminogen activator and plasminogen activator inhibitor-1 in stroke patients.中风患者体内的组织型纤溶酶原激活剂和纤溶酶原激活物抑制剂-1
Stroke. 1996 Jun;27(6):1066-71. doi: 10.1161/01.str.27.6.1066.
7
Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study.在斯德哥尔摩心脏流行病学项目(SHEEP)研究中,血浆组织型纤溶酶原激活剂/纤溶酶原激活剂抑制剂-1复合物水平和血管性血友病因子是复发性心肌梗死的重要风险标志物。
Arterioscler Thromb Vasc Biol. 2000 Aug;20(8):2019-23. doi: 10.1161/01.atv.20.8.2019.
8
Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis.组织型纤溶酶原激活物和纤溶酶原激活物抑制剂在精神病中的潜在生物标志物作用。
Asian J Psychiatr. 2019 Jun;43:105-110. doi: 10.1016/j.ajp.2019.05.021. Epub 2019 May 13.
9
[Tissue-type plasminogen activator (T-PA) and plasminogen activator inhibitor (PAI-1) in human follicular fluid during gonadotropin-induced ovulation].促性腺激素诱导排卵期间人卵泡液中的组织型纤溶酶原激活剂(T-PA)和纤溶酶原激活剂抑制剂(PAI-1)
Ginekol Pol. 2003 Oct;74(10):1386-91.
10
Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.乳腺癌患者血浆和肿瘤组织提取物中纤溶酶原激活物系统成分的测定:欧洲癌症研究与治疗组织(EORTC)受体与生物标志物小组合作项目
Oncol Rep. 2005 Jul;14(1):235-9.

引用本文的文献

1
Current research progress on the use of traditional Chinese medicine in the treatment of diabetic foot ulcers.中药治疗糖尿病足溃疡的当前研究进展
Front Endocrinol (Lausanne). 2025 Aug 22;16:1637128. doi: 10.3389/fendo.2025.1637128. eCollection 2025.